CorEvitas, LLC Announces Expansion of Specialty EMR Data Services
WALTHAM, Mass. and LONDON, July 6, 2022 /PRNewswire/ — CorEvitas, LLC is pleased to announce the expansion of its services to include specialty EMR data through its specialty EMR data business unit. Health iQ Limited, a subsidiary of CorEvitas, has provided innovative real-world evidence solutions in the UK and Europe for more than 10 years. The organization is poised to offer expanded real-world datasets and innovative, custom technology solutions as it rebrands and fully integrates with CorEvitas.
President of the Specialty EMR Data activity, Jilani Gulamshares, “This rebranding and use of the company’s trade name completes our integration with our parent company and solidifies our commitment to providing true excellence in real-world evidence solutions.”
The Specialty EMR Data business provides access to curated datasets, including US retinal EMR data, as well as UK and European primary and secondary care datasets, to advance understanding of the health of population. Additionally, with a suite of innovative software-as-a-service tools that leverage these datasets, advanced algorithms and data analytics can be applied to economic and health outcomes research, as well as commercial applications.
CorEvitas captures a holistic view of the patient, providing expanded insights and the best real-world evidence. CorEvitas’ access to in-depth clinical registry data, which includes patient-reported outcomes, its precision medicine biodepot services, and its patient voice capture experience, provides a broader view of patients’ lived experience. patients on therapies.
CorEvitas is the leading provider of real-world evidence. Through syndicated registry data and analytical services, CorEvitas provides biopharmaceutical companies with the tools to demonstrate the value of their products to clinicians, patients, payers and regulators. CorEvitas operates eight major autoimmune and inflammatory registries in the United States, Canadaand Japan, collecting data from nearly 500 participating investigator sites. In addition to contributing hundreds of manuscripts and abstracts, CorEvitas supports post-approval safety studies required by US and European regulatory authorities for several newly approved treatments in autoimmune diseases. CorEvitas has built on its syndicated registry business with additional add-on capabilities over time. The Precision Medicine business advances molecular understanding of disease and prognostic tools by combining registry data with selected biological samples and omics data. The Patient Experience business complements and reinforces the company’s strong presence in disease registries by providing industry-leading expertise in supporting innovative, evidence-based patient engagement initiatives throughout the product lifecycle. This includes the HealthUnlocked technology platform, which houses more than 1.5 million patients in hundreds of condition-specific communities, dramatically expanding the reach of experiential patient data. The Specialty EMR Data business’s close relationships with the NHS and leading UK academic institutions allow CorEvitas access to a wide range of UK and international primary and secondary care datasets, including access to a leading retinal dataset. CorEvitas is headquartered in Waltham, MA and is a portfolio company of Audax Private Equity.
+1 (508) 408-5529